You are here: Welcome » barda

Menu

Rounding The Earth

Operation Uplift

Project List

This is an old revision of the document!

BARDA - Biomedical Advanced Research and Development Authority

The Biomedical Advanced Research and Development Authority is a U.S. Department of Health and Human Services office responsible for the procurement and development of medical countermeasures created in 2006. Together with its industry partners, BARDA promotes the advanced development of medical countermeasures.

The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear CBRN accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).

Together with its industry partners, BARDA promotes the advanced development of medical countermeasures to protect Americans and respond to 21st century health security threats.1)

BARDA Director

Director, Biomedical Advanced Research and Development Authority Deputy Assistant Secretary for Preparedness and Response U.S. Department of Health and Human Services

Dr. Gary Disbrow is the Director of the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.2)

BARDA’s Expanding COVID-19 Medical Countermeasure Portfolio

BARDA has a proven track record of responding to pandemics and developing lifesaving medical countermeasures. We are rapidly executing new partnerships and building a robust COVID-19 MCM Portfolio because Americans deserve to have safe, effective medical products.3)

This page is updated regularly, but may not include all awards

All (98) Vaccines (7) Diagnostics (55) Therapeutics (16) Rapidly Deployable Capabilities (15) Other (5)

  • Pfizer Inc.
  • Paxlovid
  • EUA Issued
  • Learn More
  • GlaxoSmithKline
  • sotrovimab
  • EUA Issued
  • Learn More
  • Molnupiravir
  • EUA Issued
  • Learn More
  • Eli Lilly and Company
  • Bamlanivimab and etesevimab administered together
  • EUA Issued
  • Learn More
  • Commercial Scale Manufacturing
  • Pfizer Inc.
  • COMIRNATY (COVID-19 Vaccine, mRNA)
  • Licensed
  • Learn More
  • BD (Becton Dickinson and Company)
  • BD COR System Respiratory Panel
  •  
  • Learn More
  • BD (Becton Dickinson and Company)
  • BD MAX System Respiratory Panel plus Pan-Coronavirus
  •  
  • Learn More
  • BD (Becton Dickinson and Company)
  • BD COR System Respiratory Panel plus Pan-Coronavirus
  •  
  • Learn More
  • BD (Becton Dickinson and Company)
  • BD Veritor Plus System Respiratory Panel
  •  
  • Learn More
  • BD (Becton Dickinson and Company)
  • BD MAX System Respiratory Panel
  •  
  • Learn More
  • OraSure Technologies, Inc
  • SARS-CoV-2 Antibody ELISA for use with OraSure® Oral Antibody Collection Device
  •  
  • Learn More
  • OraSure Technologies, Inc
  • InteliSwab™ COVID-19 Rapid Test
  • EUA Issued
  • Learn More
  • OraSure Technologies, Inc
  • InteliSwab™ COVID-19 Rapid Test Rx
  • EUA Issued
  • Learn More
  • OraSure Technologies, Inc
  • InteliSwab™ COVID-19 Rapid Test Pro
  • EUA Issued
  • Learn More
  • SAb Biotherapeutics, Inc.
  • SAB-185 (anti-SARS-CoV-2 human immunoglobulin)
  • Phase 3
  • Learn More
  • [Manufacturing Demonstration Project]
  • Sanofi Pasteur and GSK GlaxoSmithKline
  • Recombinant SARS-CoV-2 Protein Antigen + AS03 Adjuvant
  • Phase 3
  • Learn More
  • Cepheid
  • Xpert  Xpress SARS-CoV-2/Flu/RSV test 
  • EUA Issued
  • Learn More
  • Cepheid
  • Xpert Pan-Coronavirus test panel
  •  
  • Learn More
  • Cepheid
  • Xpert Xpress SARS-CoV-2 test
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • LightDeck Diagnostics
  • LightDeck® COVID-19 Antigen Test
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • LightDeck Diagnostics
  • LightDeck® COVID-19 Total Antibody Test
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • ModernaTX, Inc.
  • SARS-CoV-2 mRNA-1273 vaccine
  • EUA Issued
  • Learn More
  • Dascena Inc.
  • COViage™: Machine Learning Software for COVID-19 Severity Predictions
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • DiaSorin Inc.
  • LIAISON SARS-CoV-2 TrimericS IgG Assay
  • EUA Issued
  • Learn More
  • DiaSorin Inc.
  • LIAISON SARS-CoV-2 IgM Test
  • EUA Issued
  • Learn More
  • DiaSorin Inc.
  • LIAISON SARS-CoV-2 S1/S2 IgG
  • EUA Issued
  • Learn More
  • AgileMD
  • eCART
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • Siemens Healthineers
  • ADVIA Centaur® SARS-CoV-2 Antigen (CoV2Ag) Test
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • Siemens Healthineers
  • Atellica® IM SARS-CoV-2 Antigen (CoV2Ag) Test
  •  
  • Learn More
  • Siemens Healthineers
  • Atellica® IM SARS-CoV-2 Total (COV2T) assay
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • Ortho Clinical Diagnostics
  • VITROS® SARS-CoV-2 Ag (Antigen) Test
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • Ortho Clinical Diagnostics
  • VITROS® Anti-SARS-CoV-2 IgG Test (Improved)
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • Ortho Clinical Diagnostics
  • VITROS® Anti-SARS-CoV-2 Total Test (Improved)
  •  
  • Learn More
  • Siemens Healthineers
  • ADVIA Centaur® SARS-CoV-2 Total (COV2T) assay
  • EUA Issued
  • Learn More
  • PeraHealth Inc.
  • Rothman Index Risk Triage Tool
  •  
  • Learn More
  • Philips North America
  • Philips Lumify Ultrasound
  •  
  • Learn More
  • CIADM at Emergent Biosolutions
  • Human immune Globulin for COVID-19 (COVID-19 HIG)
  • Phase 3
  • Learn More
  • [Manufacturing Demonstration Project]
  • Janssen Pharmaceuticals, Inc.
  • AD26.COV2.S - Viral Vector Vaccine for COVID-19
  • EUA Issued
  • Learn More
  • DiaSorin SpA
  • DiaSorin LIAISON SARS-CoV-2 Antigen
  • EUA Issued
  • Learn More
  • [Manufacturing Demonstration Project]
  • AstraZeneca
  • Evusheld (tixagevimab co-packaged with cilgavimab and administered together)
  • EUA Issued
  • Learn More
  • Luminex Corporation
  • Combined ARIES® Flu A/B/RSV + SARS-CoV-2 Assay
  •  
  • Learn More
  • Luminex Corporation
  • NxTAG® RPP v2 with SARS-CoV-2
  •  
  • Learn More
  • Luminex Corporation
  • xMAP® SARS-CoV-2 IgG Neutralizing Antibody Assay
  •  
  • Learn More
  • Luminex Corporation
  • ARIES® SARS-CoV-2 Assay
  • EUA Issued
  • Learn More
  • Luminex Corporation
  • NxTAG® CoV Extended Panel
  • EUA Issued
  • Learn More
  • Visby Medical Inc.
  • Visby Medical Flu & COVID-19 test
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • Hologic, Inc.
  • Panther Fusion SARS-CoV-2/Flu/RSV assay
  •  
  • Learn More
  • [Commercial Scale Manufacturing]
  • Hologic, Inc.
  • Aptima® SARS-CoV-2/Flu Assay
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • Hologic, Inc.
  • Aptima® SARS-CoV-2 assay
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • Hologic, Inc.
  • Panther Fusion SARS-CoV-2 Assay
  • EUA Issued
  • Learn More
  • [Manufacturing Demonstration Project]
  • Regeneron Pharmaceuticals, Inc
  • Casirivimab & Imdevimab (SARS-CoV-2 specific monoclonal antibodies)
  • EUA Issued
  • Learn More
  • DiaSorin Molecular LLC
  • Simplexa™ COVID-19 and Flu A/B Direct Assay
  •  
  • Learn More
  • DiaSorin Molecular LLC
  • Simplexa™ COVID-19 Direct Assay
  • EUA Issued
  • Learn More
  • Chembio Diagnostics Inc.
  • DPP® Respiratory Panel Antigen Test System
  •  
  • Learn More
  • Chembio Diagnostics Inc.
  • DPP® SARS-CoV-2 Antigen
  •  
  • Learn More
  • Mesa Biotech, Inc.
  • Accula® Flu A/B and SARS-CoV-2 Integrated Test
  •  
  • Learn More
  • Mesa Biotech, Inc.
  • Accula® SARS-CoV-2 Diagnostic Test
  • EUA Issued
  • Learn More
  • Humanigen
  • Lenzilumab
  • Phase 3
  • Learn More
  • [Commercial Scale Manufacturing]
  • InBios International, Inc.
  • SCoV-2 Detect™ IgG Rapid Test
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • InBios International, Inc.
  • SCoV-2 Ag Detect™ Rapid Test
  • EUA Issued
  • Learn More
  • [Commercial Scale Manufacturing]
  • AstraZeneca
  • AZD1222 (formerly ChAdOx1 nCoV-19 vaccine)
  • Phase 3
  • Learn More
  • Beckman Coulter
  • Monocyte Distribution Width (MDW) hematology-based biomarker
  •  
  • Learn More
  • Current Health
  • Continuous Monitoring Platform & Algorithm for COVID-19 Severity
  •  
  • Learn More
  • 98point6
  • Text-based virtual care to assess, diagnose and treat COVID-19
  •  
  • Learn More
  • NOWDiagnostics Inc.
  • ADEXUSDx® COVID-19 Serology Test
  • EUA Issued
  • Learn More
  • University of Connecticut
  • Single-Administration Microneedle Skin Patch for Pandemic Vaccine
  •  
  • Learn More
  • Vaxess Technologies, Inc.
  • MIMIX-COVID Pre-fusion Spike Protein Micro Array Patch
  •  
  • Learn More
  • Esperovax, Inc.
  • Egress RD mRNA Oral Cellular Vaccine Delivery Technology
  •  
  • Learn More
  • Verndari, Inc.
  • VaxiPatch™ Complete Vaccination Kit
  •  
  • Learn More
  • [Manufacturing Demonstration Project]
  • Novavax Inc.
  • NVX-CoV-2373 Vaccine for SARS-CoV-2
  • Phase 3
  • Learn More
  • Sonica Health
  • Sonica's Bio-Integrated, Wireless Sensor System (ADAM) System
  •  
  • Learn More
  • Empatica, Inc.
  • Aura
  •  
  • Learn More
  • Immunexpress Inc.
  • SeptiCyte RAPID Host-Based Sepsis In Vitro Diagnostic
  •  
  • Learn More
  • Sepsis Alliance
  • Sepsis COVID-19 webinars
  •  
  • Learn More
  • Quidel Corporation
  • Point of Care SARS-CoV-2 Sofia 2 Antigen Assay
  •  
  • Learn More
  • Genentech USA, Inc.
  • MSTT1041A (anti-ST2) and UTTR1147A (IL-22Fc)
  • Phase 2
  • Learn More
  • VitalConnect
  • Vista Solution
  •  
  • Learn More
  • Beckman Coulter
  • Monocyte Distribution Width (MDW) and Algorithms for Sepsis Detection
  •  
  • Learn More
  • Cerus Corporation
  • INTERCEPT Blood System
  •  
  • Learn More
  • Evidation Health
  • COVID-19 Detection & Forecasting Model Pilot
  •  
  • Learn More
  • Tangen Biosciences
  • Tangen SARS-CoV-2 Assay
  •  
  • Learn More
  • Cytovale Inc.
  • Rapid Sepsis Diagnostic
  •  
  • Learn More
  • Grifols Shared Services North America, Inc. (Grifols)
  • Convalescent plasma and hyperimmune globulin
  • Phase 3
  • Learn More
  • Nanomix
  • Nanomix eLab® COVID-19 Rapid IgG/IgM Antibody Panel
  •  
  • Learn More
  • Nanomix
  • Nanomix eLab® COVID-19 Rapid Antigen Panel
  •  
  • Learn More
  • Genentech USA, Inc.
  • ACTEMRA (tocilizumab)
  • EUA Issued
  • Learn More
  • Vela Diagnostics USA, Inc.
  • ViroKey™ SARS-CoV-2 RT-PCR Test (Manual)
  • EUA Issued
  • Learn More
  • Vela Diagnostics USA, Inc.
  • ViroKey™ SARS-CoV-2 RT-PCR Test v2.0 (Automated)
  • EUA Issued
  • Learn More
  • Cue Health Inc.
  • Point-of-Care COVID-19 Cue Health Monitoring System & Mobile App
  • EUA Issued
  • Learn More
  • GenMark Diagnostics, Inc.
  • ePlex Respiratory Pathogen v2 Panel
  • EUA Issued
  • Learn More
  • Qiagen, LLC
  • QIAstat-Dx Respiratory SARS-CoV-2 Panel
  • EUA Issued
  • Learn More
  • Janssen Research & Development, LLC
  • SARS-CoV-2 Therapeutic Drug Screening Efforts
  •  
  • Learn More
  • Merck Sharp & Dohme Corp.
  • MK-7110
  •  
  • Learn More
  • Eli Lilly and Company
  • Bamlanivimab (LY-CoV555)
  •  
  • Learn More
  • Merck and IAVI
  • rVSVΔG-CoV2 
  •  
  • Learn More
  • Hememics
  • Rapid SARS-CoV-2 Antibody Test for HemBox™ Biosensor System
  •  
  • Learn More
  • Hememics
  • Rapid SARS-CoV-2 Antigen Test for HemBox™ Biosensor System
  •  
  • Learn More
  • Regeneron Pharmaceuticals, Inc
  • Sarilumab
  • Phase 2/3
  • Learn More 4)

BARDA 2022-2026 Strategic Plan

STATEMENT FROM THE BARDA DIRECTOR, GARY DISBROW, PhD On the release of BARDA's Strategic Plan 2022-2026 5) 6)

Strategic Plan pdf

Table of Contents

Preface from the BARDA Director………….. 1

As the Biomedical Advanced Research and Development Authority enters its 16th year, we are re- leasing a new Strategic Plan focused on strengthening the health security of the nation, embracing lessons learned from the COVID-19 pandemic, incorporating new avenues of promising research and development, and addressing the imperative for medical countermeasures that are safe, effective, and widely accessible to all Americans.

BARDA understands the importance of delivering lifesaving medical countermeasures quickly, which requires a sustainable, mission-ready response posture with a workforce of scientists and other experts who can readily adapt to protect Americans from emerging threats.

This blueprint creates a framework on which the nation’s preparedness and response is strengthened by a world-class workforce and diverse public-private partnerships.

Although the COVID-19 pandemic spotlighted both new and known challenges in the nation’s pandem- ic preparedness and response strategy, the intrinsic flexibility of BARDA’s comprehensive partnership model and portfolio approach allowed a rapid pivot and acceleration in the development of vaccines, diagnostics, and therapeutics against COVID-19.

These investments also helped to improve the manufacturing and fill-finish capacity for seasonal influenza vaccines, demonstrating that sustained investment in the pandemic influenza strategy will equip BARDA with the ability to rapidly respond to emerging and reemerging pandemic pathogens.

In addition to supporting nearly 100 products as part of the COVID-19 portfolio, BARDA has supported 62 U.S. Food and Drug Administration approvals, licensures or clearances, four products used to halt Ebola outbreaks in western Africa, and more than 18 products in development for antibiotic resistance, one of the top global health threats.

This plan sets out how BARDA will continue to work with our partners to further secure the nation during public health emergencies including expanding the domestic supply chain for production of sterile injectables.

The COVID-19 pandemic has highlighted that new and innovative approaches are required to appropriately respond during a large-scale public health emergency. BARDA will emphasize innovation across all sectors of our portfolio. BARDA has established an ecosystem of innovation to include CARB-X, BARDA Ventures, an Accelerator Network, and the Blue Knight program.

Consistent with the American Pandemic Preparedness Plan and other policies, BARDA scientists, technical experts, and contracting professionals leverage unique authorities granted by Congress to promote innovation, support advanced research and development, and facilitate procurement of medical countermeasures.

Effectively preparing for future pandemics and other health security threats, we must embrace ideas and creativity from private-sector partners both large and small so that the resulting medical countermeasures serve the needs of the diverse populations we serve. Building and supporting a more inclusive, diverse workforce further enhances this capability and capacity and enables BARDA’s decision-making to reflect a broader and deeper understanding of real-world application of medical countermeasures.

BARDA will fortify the nation’s health security with our partners, stakeholders, and workforce. This Strategic Plan establishes how this will be achieved in BARDA’s next five years. Gary Disbrow, Ph.D.

Introduction……………………………. 3

Biomedical Advanced Research and Development Authority……… 4

BARDA’s Five-Year Strategic Plan………… 5

Goal 1: Preparedness: Rapidly develop safe, effective medical countermeasures accessible to all Americans ………… 7

Objective 1.1: Accelerate the development of agile MCMs that can pivot and be brought to scale in response to new threats………….. 7

Objective 1.2: Catalyze innovation across the MCM development pipeline……………………………………… 9

Objective 1.3: Embrace end-user needs and promote interventions across the continuum of care…. 10

Objective 1.4: Protect all members of our communities against an evolving threat landscape.. 11

Goal 2: Response: Enhance and maintain a sustainable, mission-ready response posture …. 13

Objective 2.1: Enhance BARDA’s response posture by leveraging a diverse MCM portfolio of proven technologies….. 13

Objective 2.2: Build a resilient, surge-capable, flexible manufacturing ecosystem that prioritizes increased domestic capacity…… 15

Objective 2.3: Enhance and sustain response-ready support services………… 16

Objective 2.4: Leverage acquisition vehicles that enable rapid response……. 17

Objective 2.5: Ensure BARDA’s response posture accounts for the needs of all segments of the population….. 18

Goal 3: Partnerships: Leverage mechanisms to foster flexible partnerships……… 19

Objective 3.1: Advance new, adaptable partnership models………… 19

Objective 3.2: Foster existing and establish new partnerships……….. 20

Objective 3.3: Enhance sustainability by supporting development and repurposing of products and technologies with commercial value….. 21

Objective 3.4: Expand partnerships with socially and economically disadvantaged businesses 22

Goal 4: Workforce: Build and support a world class workforce …….. 23

Objective 4.1: Recruit and retain leading experts across the BARDA enterprise….. 23

Objective 4.2: Promote diversity across BARDA ……….. 24

Objective 4.3: Expand career development and mentorship opportunities… 25

Objective 4.4: Adopt modern business, analytics, and communications tools to enhance efficiency. 25

Appendices…………. 27

Appendix 1:

BARDA’s Contributions to the COVID-19 Pandemic Response…. 27

COVID-19 Accomplishments………… 27

BARDA COVID-19 Vaccine Investments…… 28

BARDA COVID-19 Therapeutic Investments………… 29

BARDA COVID-19 Diagnostic Investments…. 29

Appendix 2: Overview of Key Legislation…………. 317)

1)
https://web.archive.org/web/20211204054159/https://aspr.hhs.gov/AboutASPR/ProgramOffices/BARDA/Pages/default.aspx
2)
https://web.archive.org/web/20211204020352/https://aspr.hhs.gov/AboutASPR/LeadershipBiographies/Pages/Leadership-Disbrow.aspx
3) , 4)
https://web.archive.org/web/20211203211815/https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx
5)
https://web.archive.org/web/20220601104851/https://medicalcountermeasures.gov/barda/strategic-plan/
6)
https://web.archive.org/web/20220530120433/https://www.medicalcountermeasures.gov/media/38722/barda-strategic-plan-2022-2026_one-pager-v10_asprcomms_508.pdf
7)
https://web.archive.org/web/20221219194038/https://medicalcountermeasures.gov/media/38717/barda-strategic-plan-2022-2026.pdf
Back to top